GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » Gross Profit

PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Gross Profit : $0.82 Mil (TTM As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals Gross Profit?

PhaseBio Pharmaceuticals's gross profit for the three months ended in Jun. 2022 was $0.21 Mil. PhaseBio Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2022 was $0.82 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. PhaseBio Pharmaceuticals's gross profit for the three months ended in Jun. 2022 was $0.21 Mil. PhaseBio Pharmaceuticals's Revenue for the three months ended in Jun. 2022 was $0.21 Mil. Therefore, PhaseBio Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2022 was N/A%.

PhaseBio Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage


PhaseBio Pharmaceuticals Gross Profit Historical Data

The historical data trend for PhaseBio Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals Gross Profit Chart

PhaseBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Profit
Get a 7-Day Free Trial - 0.67 2.36 - 10.83

PhaseBio Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.34 0.34 0.16 0.12 0.21

Competitive Comparison of PhaseBio Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseBio Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's Gross Profit falls into.



PhaseBio Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

PhaseBio Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )=Revenue - Cost of Goods Sold
=10.831 - 0
=10.83

PhaseBio Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2022 is calculated as

Gross Profit (Q: Jun. 2022 )=Revenue - Cost of Goods Sold
=0.208 - 0
=0.21

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

PhaseBio Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2022 is calculated as

Gross Margin % (Q: Jun. 2022 )=Gross Profit (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.21 / 0.208
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


PhaseBio Pharmaceuticals  (OTCPK:PHASQ) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PhaseBio Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage


PhaseBio Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Executives
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt officer: VP, Human Resources C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall officer: Chief Commercial Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance officer: VP, Research and Sci. Affairs C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York officer: VP, Corporate Development C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee officer: Chief Medical Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold officer: VP, Preclinical and Chem C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson officer: VP, Head of Legal C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355

PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of MAI Capital Management

By GuruFocus Research GuruFocus Editor 07-19-2022

PhaseBio Provides Pemziviptadil (PB1046) Program Update

By Business Wire Business Wire 12-21-2021